Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations

NCT04969029 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Immunotherapy
Adjuvant Therapy
Colon Cancer
MSI-H

Interventions

DRUG: Tirelizumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital